GAA and type 2 diabetes mellitus: A study comparing the effects of the combination of acarbose (alpha glucosidase inhibitors) and metformin therapy with acarbose monotherapy in the treatment of T2D reported that the combination treatment could greatly improve glycemic control in T2D individuals with a significant reduction in HbA1c, fasting plasma glucose, and postprandial glucose compared to baseline (p < 0.0001).